» Articles » PMID: 18303113

Transcriptome Sequencing of Malignant Pleural Mesothelioma Tumors

Abstract

Cancers arise by the gradual accumulation of mutations in multiple genes. We now use shotgun pyrosequencing to characterize RNA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control tissues. On average, 266 Mb of cDNA were sequenced from each of four MPMs, from a control pulmonary adenocarcinoma (ADCA), and from normal lung tissue. Previously observed differences in MPM RNA expression levels were confirmed. Point mutations were identified by using criteria that require the presence of the mutation in at least four reads and in both cDNA strands and the absence of the mutation from sequence databases, normal adjacent tissues, and other controls. In the four MPMs, 15 nonsynonymous mutations were discovered: 7 were point mutations, 3 were deletions, 4 were exclusively expressed as a consequence of imputed epigenetic silencing, and 1 was putatively expressed as a consequence of RNA editing. Notably, each MPM had a different mutation profile, and no mutated gene was previously implicated in MPM. Of the seven point mutations, three were observed in at least one tumor from 49 other MPM patients. The mutations were in genes that could be causally related to cancer and included XRCC6, PDZK1IP1, ACTR1A, and AVEN.

Citing Articles

Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseases.

Vandenhoeck J, Ibrahim J, De Meulenaere N, Peeters D, Raskin J, Hendriks J Clin Epigenetics. 2024; 16(1):176.

PMID: 39627815 PMC: 11616176. DOI: 10.1186/s13148-024-01790-z.


Malignant Pleural Mesothelioma Mutations in Reveal Synthetic Lethality between / and the Proteasome Subunit /.

Martinez-Fernandez C, Jha S, Aliagas E, Holmberg C, Nadal E, Ceron J Cells. 2023; 12(6).

PMID: 36980270 PMC: 10047281. DOI: 10.3390/cells12060929.


DNA repair and damage pathways in mesothelioma development and therapy.

Malakoti F, Targhazeh N, Abadifard E, Zarezadeh R, Samemaleki S, Asemi Z Cancer Cell Int. 2022; 22(1):176.

PMID: 35501851 PMC: 9063177. DOI: 10.1186/s12935-022-02597-9.


Preclinical Models and Resources to Facilitate Basic Science Research on Malignant Mesothelioma - A Review.

Johnson B, Takahashi K, Cheng Y Front Oncol. 2021; 11:748444.

PMID: 34900693 PMC: 8660093. DOI: 10.3389/fonc.2021.748444.


Deep Sequencing Analysis Identified a Specific Subset of Mutations Distinctive of Biphasic Malignant Pleural Mesothelioma.

Torricelli F, Lococo F, Di Stefano T, Lorenzini E, Piana S, Valli R Cancers (Basel). 2020; 12(9).

PMID: 32872534 PMC: 7563974. DOI: 10.3390/cancers12092454.


References
1.
Chau B, Cheng E, Kerr D, Hardwick J . Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell. 2000; 6(1):31-40. View

2.
Fischer H, Stenling R, Rubio C, Lindblom A . Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 2001; 22(6):875-8. DOI: 10.1093/carcin/22.6.875. View

3.
Walker J, Corpina R, Goldberg J . Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature. 2001; 412(6847):607-14. DOI: 10.1038/35088000. View

4.
Zou T, Selaru F, Xu Y, Shustova V, Yin J, Mori Y . Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene. 2002; 21(31):4855-62. DOI: 10.1038/sj.onc.1205613. View

5.
Pylkkanen L, Sainio M, Ollikainen T, Mattson K, Nordling S, Carpen O . Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep. 2002; 9(5):955-9. View